Introduction: The Rising Burden of Nephropathy and the Promise of Immunomodulation

Nephropathy—encompassing a spectrum of kidney diseases such as diabetic nephropathy, IgA nephropathy, membranous nephropathy, and lupus nephritis—remains a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. Despite advances in renin-angiotensin-aldosterone system blockade and glycemic control, many patients continue to progress toward dialysis or transplantation. In recent years, a deeper understanding of the immune system’s role in driving glomerular injury has spurred the development of novel immunomodulatory agents that target specific inflammatory and autoimmune pathways. This article evaluates the clinical efficacy of these emerging therapies, highlighting pivotal trial data, limitations, and future directions for integrating immunomodulation into standard nephropathy care.

The global prevalence of CKD exceeds 10% in many populations, and immune-mediated nephropathies disproportionately affect younger adults, leading to decades of disability and healthcare burden. Traditional therapies such as high-dose corticosteroids and cyclophosphamide, while effective, carry substantial toxicity. Newer immunomodulators aim to offer a more targeted, safer, and durable alternative. We examine the evidence across the most promising classes, from monoclonal antibodies to complement inhibitors, and discuss how these agents are reshaping treatment paradigms.

The Immune Basis of Nephropathy: From Autoimmunity to Fibrosis

The pathogenesis of many nephropathies involves dysregulated immune responses that lead to glomerular inflammation, podocyte injury, and progressive fibrosis. In autoimmune glomerulonephritis such as lupus nephritis and ANCA-associated vasculitis, autoantibodies and immune complexes trigger complement activation, recruitment of T cells and macrophages, and release of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interferon-gamma. Sustained inflammation disrupts the glomerular filtration barrier, resulting in proteinuria and declining renal function. Meanwhile, in diabetic nephropathy, metabolic stress activates innate immunity and promotes low-grade inflammation, contributing to mesangial expansion and tubulointerstitial fibrosis. Immunomodulatory agents aim to interrupt these cascades at key checkpoints, thereby preserving nephron mass and delaying disease progression.

More recently, the role of the alternative complement pathway in C3 glomerulopathy and the importance of B-cell activating factor (BAFF) in lupus nephritis have been elucidated. These insights have directly led to the development of targeted therapies that block specific molecules rather than suppressing the entire immune system. Understanding the immune landscape of each nephropathy subtype is critical for selecting the appropriate immunomodulatory strategy.

Overview of Immunomodulatory Agents in Nephropathy

A new generation of targeted therapies has emerged, each designed to modulate distinct components of the immune system. These include monoclonal antibodies, cytokine inhibitors, complement inhibitors, and cell-based therapies. Below we examine the rationale and clinical evidence for the most promising classes.

Monoclonal Antibodies

Monoclonal antibodies (mAbs) have become a cornerstone of precision immunomodulation. Rituximab, a chimeric mAb directed against CD20 on B cells, depletes circulating B cells and reduces autoantibody production. It has demonstrated efficacy in membranous nephropathy and ANCA-associated vasculitis. Newer agents such as belimumab, which inhibits B-cell activating factor (BAFF), have shown additive benefits in lupus nephritis when combined with standard immunosuppression. Another mAb, obinutuzumab, is under investigation for its enhanced B-cell depletion capabilities and potential in rituximab-resistant disease. Obinutuzumab’s glycoengineered Fc region allows for more potent antibody-dependent cellular cytotoxicity and apoptosis, leading to deeper and more durable B-cell depletion.

Beyond B-cell targeting, monoclonal antibodies against T-cell costimulatory molecules are being explored. For instance, abatacept (CTLA4-Ig) disrupts CD28-CD80/86 interactions and has shown benefit in a subset of patients with lupus nephritis and IgA nephropathy. However, results have been inconsistent, highlighting the need for patient selection based on immune endotypes.

Cytokine Inhibitors

Blocking key inflammatory cytokines offers an alternative strategy. TNF-α inhibitors such as etanercept and infliximab have been explored in disorders like IgA nephropathy and rheumatoid arthritis-associated nephritis, though results have been mixed. More recently, IL-6 receptor antagonists (e.g., tocilizumab) and IL-1 inhibitors (e.g., anakinra) have entered trials for conditions such as systemic lupus erythematosus and vasculitis, with early signals of reduced disease activity and proteinuria. The selectivity of these agents may limit off-target toxicity compared with broad immunosuppressants like cyclophosphamide.

Another emerging target is the IL-23/Th17 axis. Agents such as ustekinumab (anti-IL-12/23) and secukinumab (anti-IL-17) are being investigated for psoriasis and psoriatic arthritis which can involve renal manifestations. While direct nephropathy data are limited, the proinflammatory role of IL-17 in kidney fibrosis suggests potential utility. A small pilot study of ustekinumab in lupus nephritis showed stable renal function over 24 weeks, warranting larger trials.

Complement Inhibitors

The complement cascade is a critical mediator of tissue damage in several nephropathies, particularly C3 glomerulopathy, atypical hemolytic uremic syndrome (aHUS), and lupus nephritis. Eculizumab, a monoclonal antibody that blocks complement component C5, is approved for aHUS and has been investigated in C3 glomerulopathy with variable success. Newer agents targeting factor B, factor D, and C3 (e.g., avacopan, iptacopan) offer more proximal complement inhibition, potentially reducing the formation of membrane attack complexes and inflammatory anaphylatoxins. Avacopan has shown promise in ANCA-associated vasculitis as a steroid-sparing agent, achieving noninferiority to high-dose glucocorticoids for remission induction in the ADVOCATE trial.

Iptacopan, an oral factor B inhibitor, has demonstrated robust reductions in proteinuria and stabilization of eGFR in a phase 2 trial of C3 glomerulopathy. A phase 3 trial (APPEAR-C3G) is currently recruiting. For aHUS, eculizumab has transformed prognosis, but its high cost and requirement for intravenous administration spurred development of ravulizumab, a long-acting C5 inhibitor with extended dosing intervals. Real-world registries continue to confirm the importance of early complement blockade in preserving renal function.

Cell-Based Therapies

Regulatory T cells (Tregs) and mesenchymal stromal cells (MSCs) represent a frontier in nephropathy immunotherapy. Treg therapy aims to restore immune tolerance by suppressing autoreactive effector cells, while MSCs exhibit anti-inflammatory and reparative properties. Early-phase trials in lupus nephritis and kidney transplantation have demonstrated safety and hint at efficacy, though larger studies are needed to confirm benefit and optimize cell manufacturing. In a phase 1b trial of autologous Treg infusion in lupus nephritis, patients showed reduced proteinuria and serological activity over 12 months. MSC therapy is being tested in diabetic nephropathy, with a recent meta-analysis suggesting improvements in eGFR and albuminuria in early-stage disease.

Chimeric antigen receptor (CAR) T-cell therapy, a breakthrough in oncology, is being repurposed for autoimmune diseases. Preclinical models of lupus nephritis show that CD19-targeted CAR T cells can eliminate autoreactive B cells and induce long-term remission. Clinical trials are expected to begin within the next two years, potentially representing a paradigm shift for treatment-refractory autoimmune kidney disease.

Clinical Trial Evidence: Key Outcomes and Agent Profiles

Randomized controlled trials (RCTs) remain the gold standard for evaluating immunomodulatory agents. Primary endpoints typically include complete or partial remission of proteinuria, stabilization or improvement of estimated glomerular filtration rate (eGFR), delay of dialysis initiation, and reduction in disease flares. Biomarkers such as anti-phospholipase A2 receptor (PLA2R) antibody titers in membranous nephropathy and urine protein-to-creatinine ratio are frequently used to monitor response.

Rituximab in Membranous Nephropathy

Rituximab has been extensively studied in primary membranous nephropathy. The landmark GEMRITUX trial demonstrated that six-month rituximab therapy induced higher rates of remission (proteinuria reduction to <3.5 g/day) compared to conventional therapy, with durable responses up to 5 years. Subsequent studies confirmed that anti-PLA2R antibody depletion correlates with clinical remission, enabling personalized treatment monitoring. However, not all patients respond, and relapses occur—prompting research into combination strategies with calcineurin inhibitors or belimumab. The MENTOR trial compared rituximab with cyclosporine and found rituximab superior in sustaining remission at 24 months (60% vs. 20%), with a better safety profile. Long-term follow-up data from the GEMRITUX cohort report that 70% of patients achieve stable remission without additional immunosuppression at 5 years.

Belimumab in Lupus Nephritis

In lupus nephritis, the BLISS-LN trial randomized patients receiving standard therapy (mycophenolate mofetil or cyclophosphamide) to either belimumab or placebo. At 104 weeks, the belimumab group achieved a significantly higher primary efficacy renal response (defined as eGFR ≥60 mL/min/1.73 m², urine protein-creatinine ratio ≤0.7, and no treatment failure). This led to FDA approval for belimumab in active lupus nephritis, marking a major advance in reducing corticosteroid exposure and relapse rates. Post-hoc analyses suggest that belimumab is particularly effective in patients with proliferative disease and high serological activity (elevated anti-dsDNA, low C3/C4). The ongoing BLISS-LN long-term extension shows sustained benefit through 5 years, with fewer renal flares and reduced corticosteroid use.

Complement Inhibition in C3 Glomerulopathy and aHUS

For C3 glomerulopathy, a phase 2 trial of avacopan (oral C5a receptor inhibitor) showed stabilization of eGFR and reduction in proteinuria over 26 weeks, though the endpoint for a larger phase 3 study was narrowly missed. Iptacopan (oral factor B inhibitor) is undergoing phase 3 evaluation and has shown promising biomarker improvements, including reduction in C3 deposition on renal biopsy. In aHUS, eculizumab has transformed prognosis from up to 50% mortality or dialysis to renal recovery in most patients, as demonstrated in prospective registry studies. These successes underscore the power of complement-targeting approaches for rare nephropathies. However, challenges remain: eculizumab does not fully block the alternative pathway, leading to residual disease activity in some C3-glomerulopathy patients, and the need for lifelong therapy creates cost and medication adherence issues.

JAK Inhibitors in Lupus Nephritis and Beyond

Janus kinase (JAK) inhibitors, such as baricitinib and tofacitinib, block intracellular signaling downstream of multiple cytokine receptors. In a phase 2 trial of baricitinib in lupus nephritis (NCT03616990), patients receiving 4 mg daily alongside mycophenolate showed a numerically higher rate of complete renal response at 52 weeks compared with placebo (44% vs. 30%), although the primary endpoint was not met. Subgroup analysis suggested benefit in patients with high type I interferon signatures. A larger phase 3 trial is ongoing. JAK inhibitors also hold potential in diabetic nephropathy, where the JAK-STAT pathway mediates fibrotic responses. A small phase 2 study of baricitinib in diabetic kidney disease demonstrated reduction in albuminuria and inflammatory biomarkers over 12 weeks, though longer-term renal outcomes are awaited.

Challenges in Implementing Immunomodulatory Therapies

Despite encouraging efficacy, several barriers hinder the widespread adoption of these agents.

Variability in Patient Response and Biomarkers

Not all patients derive equal benefit. In membranous nephropathy, anti-PLA2R antibody titer predicts rituximab response, but other immune-mediated nephropathies lack validated biomarkers. This leads to empiric therapy and potential exposure to ineffective treatments. Efforts to identify urinary proteomic signatures or T-cell subtypes that forecast response are ongoing but have yet to enter routine clinical practice. The heterogeneity of disease mechanisms within a single diagnostic category—for example, lupus nephritis with different histologic classes and immune endotypes—demands biomarker-guided therapy. Consortium projects like the CureGN network are collecting detailed phenotypic and genomic data to address this need.

Safety and Adverse Effects

Immunomodulators carry risks, including infusion reactions, infections (due to immunosuppression), and rare complications like progressive multifocal leukoencephalopathy (PML) with rituximab. Complement inhibitors increase susceptibility to Neisseria infections, requiring vaccination and prophylactic antibiotics. Long-term safety data remain limited for newer agents, and the potential for paradoxical autoimmunity or malignancy demands careful pharmacovigilance. Avacopan is associated with liver enzyme elevations and requires monitoring. JAK inhibitors have boxed warnings for thrombosis and malignancy, though the absolute risk appears low in the doses used for renal disease. Patient selection and risk stratification by age, comorbidity, and prior immunosuppression are essential to optimize the benefit-risk ratio.

Cost and Accessibility

Biologic agents are expensive, with annual costs often exceeding $50,000–$150,000 per patient. Reimbursement disparities and lack of infrastructure in lower-income countries restrict access. Value-based pricing models and biosimilar alternatives (e.g., rituximab biosimilars) may improve affordability, but high-cost drugs like belimumab and eculizumab remain out of reach for many. In the United States, Medicare Part B covers many infused biologics, but prior authorization requirements and patient copays create barriers. International efforts, such as the World Health Organization’s inclusion of rituximab on the Essential Medicines List, may help expand access. For complement inhibitors, the high cost of eculizumab (>$400,000 per year) has led to restrictive criteria for aHUS treatment in many countries, potentially delaying life-saving therapy.

Future Directions: Personalized Immunotherapy and Combination Regimens

The next decade promises refinement in immunomodulatory strategies for nephropathy. First, the integration of genomics and single-cell transcriptomics will enable selection of the optimal agent based on an individual’s immune profile. For example, patients with high type I interferon signatures may benefit from JAK inhibitors, while those with prominent B-cell activity may respond best to anti-CD20 or anti-BAFF agents. The advent of urine proteomics and circulating immune complex profiling offers noninvasive tools for monitoring disease activity and predicting relapses.

Second, combination therapies—such as rituximab plus belimumab or avacopan plus cyclophosphamide—may achieve synergy while reducing toxicity. The CALM trial (rituximab + belimumab in lupus nephritis) showed improved renal response rates and lower relapse rates compared to historical controls. Phase 3 studies are planned. Similarly, combining complement inhibition with B-cell depletion is being explored for C3 glomerulopathy resistant to monotherapy.

Third, the development of oral small molecules targeting intracellular signaling pathways (e.g., BTK inhibitors, SYK inhibitors, PI3Kδ inhibitors) could provide convenient alternatives to injectable biologics. BTK inhibitors such as ibrutinib and acalabrutinib are already approved for B-cell malignancies; early studies in lupus nephritis are ongoing. SYK inhibitors (e.g., fostamatinib) have shown modest benefit in IgA nephropathy, with a phase 2 trial demonstrating reduced proteinuria at 24 weeks. Oral complement inhibitors (iptacopan, pegcetacoplan) offer the advantage of home administration, potentially improving adherence and quality of life.

Regulatory agencies are increasingly accepting composite endpoints that reflect long-term kidney survival rather than short-term proteinuria alone. Adaptive trial designs and biomarker-stratified randomization can accelerate approval of targeted therapies. Collaborative international registries, such as the CureGN and RaDaR networks, are collecting real-world data to confirm efficacy and safety across diverse populations. The use of pragmatic trials and registry-based randomization will help generate evidence for less common nephropathies where large RCTs are infeasible.

Conclusion: Toward an Evidence-Based, Immunomodulatory Paradigm in Nephropathy

Immunomodulatory agents have fundamentally altered the treatment landscape for immune-mediated nephropathies. Monoclonal antibodies like rituximab and belimumab offer validated remissions in membranous nephropathy and lupus nephritis, while complement inhibitors provide life-saving options for aHUS and promise in C3 glomerulopathy. Yet challenges of response heterogeneity, cost, and long-term safety remain. As research advances our understanding of immune mechanisms at the single-cell level, the goal of personalized immunotherapy—tailoring the right agent to the right patient at the right time—becomes increasingly attainable. Clinicians caring for patients with nephropathy should stay abreast of new clinical trial data and collaborate with nephrology specialists to integrate these therapies judiciously. Continued investment in translational research and equitable access initiatives will be essential to ensure that the full potential of immunomodulation is realized for all patients with kidney disease.

The coming years will likely see the approval of oral complement inhibitors, JAK inhibitors for lupus nephritis, and possibly CAR T-cell therapy for refractory autoimmune nephropathy. As the therapeutic armamentarium expands, the challenge shifts from discovering new targets to implementing precise, cost-effective, and patient-centered treatment algorithms. Multidisciplinary care models that include immunologists, nephrologists, pharmacologists, and patient advocates will be vital to translating scientific breakthroughs into improved outcomes for the millions of patients affected by nephropathy worldwide.